Kai Yuan

793 total citations
36 papers, 603 citations indexed

About

Kai Yuan is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kai Yuan has authored 36 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kai Yuan's work include Advanced Breast Cancer Therapies (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Kai Yuan is often cited by papers focused on Advanced Breast Cancer Therapies (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Kai Yuan collaborates with scholars based in China, Poland and Denmark. Kai Yuan's co-authors include Peng Yang, Xiao Wang, Wenjian Min, Aijun Lin, Songjin Guo, Hequan Yao, Haiping Hao, Chengliang Sun, Meng Gu and Gefei Wang and has published in prestigious journals such as Nature Communications, Journal of Medicinal Chemistry and Organic Letters.

In The Last Decade

Kai Yuan

33 papers receiving 597 citations

Peers

Countries citing papers authored by Kai Yuan

Since Specialization

Citations

This map shows the geographic impact of Kai Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Yuan more than expected).

Fields of papers citing papers by Kai Yuan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Yuan. The network helps show where Kai Yuan may publish in the future.

Co-authorship network of co-authors of Kai Yuan

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Yuan. A scholar is included among the top collaborators of Kai Yuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Yuan. Kai Yuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer 2025 ·Journal of Medicinal Chemistry ·Jiaxing Li, Chengliang Sun, Ying Zhang, (unknown), Yao Peng, (unknown), (unknown), (unknown), Yasheng Zhu, (unknown), (unknown), Liping Wang, Kai Yuan, Xiao Wang, Peng Yang	0
2	Carbonic anhydrase IX-targeted SMDCs for cancer precision treatment 2025 ·Chinese Chemical Letters ·(unknown), (unknown), Guisen Li, (unknown), Yuan Shao, (unknown), Mingming Zheng, Kai Yuan, Xiaolian Sun, Peng Yang	0
3	Discovery of a Novel and Potent MET Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLC 2025 ·Journal of Medicinal Chemistry ·Wenjian Min, Chunling Chen, (unknown), (unknown), (unknown), (unknown), (unknown), Yan Zhao, Yi Hou, (unknown), Yasheng Zhu, Chengliang Sun, Kai Yuan, Peng Yang, Xiao Wang	0
4	Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer 2025 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Yuanyuan Chen, (unknown), (unknown), (unknown), (unknown), (unknown), Pan Xu, (unknown), Kai Yuan, Xiaoyu Zhang, Peng Yang	1
5	The synergistic effect of biosynthesized CuONPs and phage (ϕPB2) as a novel approach for controlling Ralstonia solanacearum 2024 ·Chemical and Biological Technologies in Agriculture ·Hongbao Zhang, Liuti Cai, Kai Yuan, (unknown), (unknown), (unknown), Cai Wu, (unknown), Lin Cai, (unknown)	1
6	Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors 2024 ·Journal of Medicinal Chemistry ·Chengliang Sun, Yuling He, Gefei Wang, Guoyu Zhang, Yu Zhang, Hao Shen, (unknown), (unknown), (unknown), Xiao Wang, Kai Yuan, Wenjian Min, Liping Wang, Haopeng Sun, Yibei Xiao, Peng Yang	13
7	Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment 2024 ·Journal of Medicinal Chemistry ·Wenjian Min, (unknown), Dawei Wang, Chunling Chen, (unknown), Yi Hou, Yasheng Zhu, Chengliang Sun, Xiao Wang, Kai Yuan, Peng Yang	6
8	Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy 2024 ·Future Medicinal Chemistry ·(unknown), Xiaoyu Zhang, (unknown), (unknown), (unknown), Kai Yuan, Peng Yang	3
9	Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer 2023 ·Journal of Medicinal Chemistry ·Kai Yuan, (unknown), (unknown), (unknown), Hongtao Shen, (unknown), (unknown), (unknown), Xiaoyu Zhang, Yibei Xiao, Peng Yang	4
10	Bispecific antibodies in cancer therapy: Target selection and regulatory requirements 2023 ·Acta Pharmaceutica Sinica B ·(unknown), Xinmiao Yu, Xiao Wang, Kai Yuan, Gefei Wang, (unknown), Guoyu Zhang, (unknown), Liping Wang, Chengliang Sun, Peng Yang	55
11	Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer 2022 ·Journal of Medicinal Chemistry ·Yi Hou, Fang Zhang, Wenjian Min, Kai Yuan, Wenbin Kuang, Xiao Wang, Yasheng Zhu, Chengliang Sun, (unknown), (unknown), Haolin Zhang, Linping Wang, Peng Yang	12
12	Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer 2022 ·Nature Communications ·Kai Yuan, (unknown), Wenbin Kuang, Xiao Wang, (unknown), (unknown), (unknown), Jiaxing Li, Wenjian Min, Chengliang Sun, (unknown), Meiling Lü, Liping Wang, Haixia Ge, Yuzhang Jiang, Haiping Hao, Yibei Xiao, Peng Yang	13
13	Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer 2022 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Hao Cheng, (unknown), (unknown), Wenjian Min, (unknown), Xiao Wang, Liping Wang, Lijuan Cao, Kai Yuan, Peng Yang	11
14	Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment 2022 ·Journal of Medicinal Chemistry ·Chengliang Sun, Mingxiao Yin, Yao Cheng, (unknown), Xiaojia Liu, Gefei Wang, Xiao Wang, Kai Yuan, Wenjian Min, Jingwen Dong, Yi Hou, (unknown), Guoyu Zhang, (unknown), Liping Wang, (unknown), Xinmiao Yu, Yibei Xiao, Hongbin Deng, Peng Yang	33
15	Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia 2021 ·European Journal of Medicinal Chemistry ·Haixia Ge, (unknown), Kai Yuan, (unknown), Hao Cheng, (unknown), (unknown), (unknown), Xiaojun Xu, Peng Yang	6
16	Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell 2021 ·Acta Pharmaceutica Sinica B ·Jiaxing Li, Xiao Wang, (unknown), Yasheng Zhu, Wenjian Min, (unknown), Kai Yuan, Chengliang Sun, Peng Yang	12
17	Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia 2021 ·Journal of Medicinal Chemistry ·Kai Yuan, (unknown), Shengnan Xie, Zhixia Qiu, (unknown), Wenjian Min, (unknown), (unknown), Xiao Wang, Jiaxing Li, Yi Hou, Wenbin Kuang, Liping Wang, Wanjian Gu, Zhiyu Li, Peng Yang	13
18	Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs 2020 ·Acta Pharmaceutica Sinica B ·Kai Yuan, Xiao Wang, (unknown), Wenjian Min, Haiping Hao, Peng Yang	103
19	Discovery of Novel and Selective CDK4/6 Inhibitors By Pharmacophore and structure-based Virtual Screening 2020 ·Future Medicinal Chemistry ·Kai Yuan, Wenjian Min, Xiao Wang, Jiaxing Li, Wenbin Kuang, Fang Zhang, Shengnan Xie, Peng Yang	14
20	Palladium-Catalyzed Cascade Heck Cyclization To Access Bisindoles 2018 ·Organic Letters ·Kai Yuan, Lina Liu, Jiayi Chen, Songjin Guo, Hequan Yao, Aijun Lin	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact